Clinical trials
Myelofibrosis clinical trials
Below are recruiting myelofibrosis clinical trials, each written for real people, not researchers. We’re tracking 88 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05875805Recruiting
Telehealth planning for future care decisions
This trial tests a telehealth (video or phone) program that helps people with certain blood cancers plan their future care preferences. It may help you and your chosen support person communicate your wishes clearly, especially if you become too sick to speak for yourself.
Rochester, New YorkAges 60 years+ - NCT05423691RecruitingPhase 1
Test drug CK0804 plus special T-cell therapy after ruxolitinib
This Phase 1 study tests CK0804 (plus T-regs, a type of immune cell approach) for people with myelofibrosis whose disease is not adequately controlled on ruxolitinib. It may help improve blood counts, symptoms, and/or the size of an enlarged spleen.
Sacramento, CaliforniaAges 18 years+ - NCT05440838Recruiting
Study factors that predict response to first-line blood cancer therapy
This study looks for factors that may predict how well people with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis respond to first treatments such as hydroxyurea or pegylated interferon. It may help doctors choose better treatments by learning what differences affect outcomes.
AngersAges 18 years+ - NCT05326919Recruiting
Study biobank for people newly diagnosed with certain blood cancers
This study follows people who are newly diagnosed (and haven’t been fully treated yet) with specific leukemia or related blood disorders to help researchers learn which treatments may work best. It may help by connecting you to a larger “precision medicine” patient group for future research.
BobignyAges Any age - NCT05198960RecruitingPhase 3
Blood thinner drugs vs aspirin to prevent clot problems
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
AngersAges 18 years+ - NCT05123365RecruitingPhase 1/Phase 2
Testing a dose of N-acetylcysteine for certain blood cancers
This Phase 1/2 study tests what dose of N-acetylcysteine (NAC) is safe and potentially helpful for people with essential thrombocythemia, polycythemia vera, or myelofibrosis. It focuses on people who still have symptoms and meet blood and health requirements so researchers can monitor side effects and symptom changes.
Irvine, CaliforniaAges 18 years+ - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT04644016RecruitingPhase 2
Cord blood transplant for children and young adults with blood cancers
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
New York, New YorkAges Up to 21 years - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT02760238Recruiting
Myeloproliferative Neoplasms patient registry study
This is a research registry for people who have certain blood cancers called myeloproliferative neoplasms (MPNs). It helps researchers learn about the disease over time and may help future studies find and compare patients.
Toronto, OntarioAges Any age - NCT07443306RecruitingPhase 2
Testing Flonoltinib for myelofibrosis after JAK inhibitor failure
This trial tests a new tablet, Flonoltinib, for people with medium-to-high risk myelofibrosis whose prior JAK inhibitor treatment stopped working, caused side effects, or wasn't tolerated. The goal is to see if this new drug can help reduce spleen size and improve symptoms.
Chengdu, SichuanAges 18–80 - NCT07863466Recruiting
Tracking outcomes for chronic blood cancers
This study follows people with certain chronic blood cancers to understand how the diseases progress and how treatments affect outcomes over time. It may help improve care for future patients.
MilanAges 16 years+ - NCT07802405RecruitingPhase 1
Testing a new drug alone or with ruxolitinib for myelofibrosis
This trial is testing a new drug called WJ01024, which may help treat myelofibrosis. It can be taken alone or with ruxolitinib, a standard treatment for this condition. The study checks safety and how well it works.
Zhengzhou, HenanAges 3 weeks+ - NCT07774455Recruiting
Pacritinib in real-world settings for myelofibrosis
This study looks at how well pacritinib works in everyday medical practice for people with myelofibrosis, a type of bone marrow disorder. It helps us understand the benefits and risks of this treatment for patients like you.
New Haven, ConnecticutAges 18 years+ - NCT07480824RecruitingPhase 1
Liver function and safety of TQ05105 tablet
This study tests how a tablet called TQ05105 is processed in people with different levels of liver function. It helps doctors understand the right dose for patients with liver problems.
Luoyang, HenanAges 18–75
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myelofibrosis?
- Yes. Clin2 currently lists 88 recruiting myelofibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myelofibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myelofibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.